CORCEPT THERAPEUTICS INC (CORT)

As of 14 August 2026, short interest in CORT is 9,696,757 shares, up 254,007 shares over the last month. Over the last 48 readings it ranged from 8,186,385 shares (15 January 2026) to 22,086,315 shares (30 August 2024). At the reported average volume of 928K shares a day that is 10.4 days to cover, a crowded short.

<iframe src="https://xoomar.com/embed/stocks/cort" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>

As of 11 September 2026, the short share of CORT volume is 83.9%, up 16.8 points over the last five sessions. Over the last 52 readings it ranged from 41.2% (18 August 2026) to 85.0% (10 July 2026). The latest reading sits at the top of that range. The latest reading is 21.6 points above the 30-session average of 62.3%, on 504K shares reported.

As of 31 July 2026, the fails-to-deliver balance in CORT is 242,856 shares, up 240,281 shares over the last settlement date. Over the last 49 readings it ranged from 1 share (17 November 2025) to 242,856 shares (31 July 2026). The latest reading sits at the top of that range.

Insiders at CORT reported 43 open-market sells worth $47.4M in the last 90 days and no open-market buys. Sells alone are a weak signal; insiders sell for tax, diversification and estate reasons all the time. Latest filing: Maduck Sean (See Remarks) on 2026-09-02.

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are the rarer, stronger signal.

8 Form 144 notices on file for CORT worth $53.9M at the prices reported; 8 in the last 90 days worth $53.9M. Latest: Vieira Roberto Wandenkolk filed on 2026-09-02 to sell 75,295 shares ($8.3M) from 2026-09-02.

2 holders above 5% have filed on CORT, all on Schedule 13G (passive). The largest reported stake is Renaissance Technologies LLC at 4.9% of the class (5,261,628 shares), filed 2026-08-13 for an event on 2026-04-01.

8 of the 30 tracked managers held CORT at their latest 13F, $873.6M in total at quarter-end prices. Renaissance Technologies is the largest at $457.5M (0.6% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 6 cut.

Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.

In Q2 2026 (quarter ended 2026-06-30) CORCEPT THERAPEUTICS INC reported revenue of $256.1M, up 31.7% from the same quarter a year earlier, and net income of $43.0M (0.36 diluted EPS). In FY 2025 it generated $142.0M of operating cash flow and spent $172.9M on buybacks.

Quarterly, last 8 quarters

Fiscal years, with buybacks and dividends

Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are cash paid to repurchase common stock in the year (XBRL PaymentsForRepurchaseOfCommonStock), not authorizations. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-22 from the cover page.